beaker banner

Chemical Biology

Jonathan Boyce, PhD

Assistant Professor

Dr. Boyce's lab develops protease-cleavable linkers for peptide prodrugs and antibody-drug conjugates (ADCs) to minimize neutropenia, a common side effect for FDA-approved protease-cleavable ADCs due to premature drug release. The Boyce lab designs biomolecular prodrugs to combat cancer resistance in ccRCC, ovarian, and breast cancers, and focuses on the chemical synthesis, medicinal chemistry optimization, and target evaluation of natural product classes with rare selectivity against cancer.

His lab's research interests focus on protease-activated prodrug development, prodrug linker optimization for cancer therapeutics, biomolecular prodrug development to combat cancer resistance, chemical synthesis of natural product analogs with rare selectivity against cancer, and synthesis of photoaffinity probes for target ID.
Other research areas: Cancer, Chemical Synthesis, Division of Medicinal Chemistry & Pharmacognosy, Natural Products, Nanotechnology & Drug Delivery Systems
Email Directory Page
Jonathan Boyce

Xiaolin Cheng, PhD

Professor

Dr. Cheng’s laboratory aims to develop an interdisciplinary research program centered on Computer Aided Drug Design and Discovery. Closely collaborating with experimental chemists and biologists, our group utilizes a myriad of computational modeling & simulation, and data analytics techniques to understand molecular basis of drug action and to rationally design new drug molecules. Our group also has long-standing interests in: a) developing and applying multiscale computational techniques to investigate the structure, dynamics and function of complex biomolecular (and cellular ) systems; and b) bridge large-scale molecular simulation with systems biology (cellular metabolism and signaling networks) towards a new drug discovery paradigm.
Other research areas: Cancer, Infectious Diseases, Computational Biomedicine & Data Analytics, Division of Medicinal Chemistry & Pharmacognosy
Email Directory Page
Xiaolin Cheng

Emanuele Cocucci, MD, PhD

Associate Professor

Dr. Cocucci studies basic mechanisms of membrane trafficking and is interested in how these processes deviate during cancer development when compared to normal cells. His research adopts multiple techniques, including traditional biochemistry, cell biology, and high resolution fluorescent live cell microscopy. Dr. Cocucci’s goal is to define novel targets for cancer therapy and to improve drug delivery, studying the internalization pathways and the mechanisms of endosomal escape adopted by artificial and biological nanovectors.
Other research areas: Cancer, Nanotechnology & Drug Delivery Systems, The Division of Pharmaceutics & Pharmacology
Email Directory Page
Emanuele Cocucci

Rajgopal Govindarajan, DVM, PhD

Chair of the Division of Pharmaceutics and Pharmacology

Dr. Govindarajan’s laboratory is interested in understanding and overcoming drug resistance in pancreatic cancer. His training is in the areas of animal sciences, cancer biology and drug transport-based pharmacokinetics, and has extensively used cell and animal models to evaluate nucleoside and oligonucleotide therapies. He also developed several new insights into the pharmacology and cytotoxicity of nucleoside analog drugs. Current focuses in his laboratory are to understand the epigenetic alterations in pancreatic cancer and to evaluate novel epigenetic reversal agents for effective pancreatic cancer treatment. Understanding epigenetic regulation of pluripotent stem cell factors in microRNA biogenesis is also of interest.
Other research areas: The Division of Pharmaceutics & Pharmacology, Cancer
Email Directory Page
Rajgopal Govindarajan

Kou-San Ju, PhD

Associate Professor

My interdisciplinary research program is inspired by the metabolic diversity of microorganisms and the vast array of compounds they produce. Working at the interface of chemistry and biology, my group combines approaches in chemistry, biochemistry, bioinformatics, genetics, and systems biology to discover new natural products, identify bioactivity and mode of action, and to decipher the metabolic basis of their biosynthesis. Ultimately, we seek to translate insights gained from our investigations into solutions for modern day challenges facing human health and the environment. These include new antibiotics to counter drug-resistant pathogens, novel herbicides and biocontrol agents to improve pest management and food security, and engineered biocatalysts to facilitate chemical production by green chemistry and industrial biotechnology.
Other research areas: Division of Medicinal Chemistry & Pharmacognosy, Central Nervous System Disorders, Infectious Diseases, Computational Biomedicine & Data Analytics, Natural Products
Email Directory Page
Kou-San Ju

Blake R. Peterson, PhD

Chair of the Division of Medicinal Chemistry & Pharmacognosy

Dr. Peterson’s research group works to design, synthesize, and discover small molecules that affect the proliferation of cancer cells and associated immune cells that support malignancy. To identify these compounds, the Peterson laboratory synthesizes fluorescent molecular probes as tools for drug discovery. These probes are used to create target-based or phenotypic drug discovery assays to identify anticancer agents with novel mechanisms of action. To optimize and evaluate these compounds, they use synthetic organic chemistry, medicinal chemistry, and chemical biology approaches. In conjunction with high throughput screening by confocal microscopy, flow cytometry, and other related techniques, his laboratory identifies chemical probes of biological systems, uncovers mechanisms of biologically active agents, and discovers hit and lead compounds for the development of therapeutics.
Other research areas: Cancer, Division of Medicinal Chemistry & Pharmacognosy, Chemical Synthesis
Email Directory Page
Blake R. Peterson